↓ Skip to main content

Flupenthixol versus placebo for schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, November 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
8 tweeters
weibo
1 weibo user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Flupenthixol versus placebo for schizophrenia
Published in
Cochrane database of systematic reviews, November 2012
DOI 10.1002/14651858.cd009777.pub2
Pubmed ID
Authors

Xiaohong Shen, Jun Xia, Clive E Adams

Abstract

Flupenthixol, first made available in the UK in 1965, has been used as a treatment for schizophrenia for decades.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 1%
South Africa 1 1%
Brazil 1 1%
Unknown 69 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 18%
Researcher 9 13%
Student > Doctoral Student 8 11%
Student > Postgraduate 7 10%
Student > Ph. D. Student 6 8%
Other 15 21%
Unknown 14 19%
Readers by discipline Count As %
Medicine and Dentistry 23 32%
Psychology 10 14%
Nursing and Health Professions 7 10%
Social Sciences 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 9 13%
Unknown 16 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2017.
All research outputs
#1,883,224
of 12,527,093 outputs
Outputs from Cochrane database of systematic reviews
#4,172
of 8,923 outputs
Outputs of similar age
#39,131
of 254,332 outputs
Outputs of similar age from Cochrane database of systematic reviews
#231
of 448 outputs
Altmetric has tracked 12,527,093 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,332 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 448 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.